Mark H Rozenbaum
Overview
Explore the profile of Mark H Rozenbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ilic A, Tort M, Cane A, Farkouh R, Rozenbaum M
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591182
(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses are administered during the first...
2.
Perdrizet J, Rozenbaum M, Heffler M
Infect Dis Ther
. 2024 Jul;
13(9):2017-2034.
PMID: 39060825
Introduction: Most European infant national immunization programs (NIPs) recommend pneumococcal conjugate vaccines (PCVs), which currently cover 10-15 serotypes administered in a three-dose schedule (two primary plus one booster). Recently, a...
3.
Rozenbaum M, Huang L, Cane A, Arguedas A, Chapman R, Dillon-Murphy D, et al.
J Med Econ
. 2024 Apr;
27(1):644-652.
PMID: 38577742
Aim: The US Food and Drug Administration approved the 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease. In the context of routine PCV20 vaccination, we evaluated the cost-effectiveness and...
4.
Rozenbaum M, Chilson E, Farkouh R, Huang L, Cane A, Arguedas A, et al.
Infect Dis Ther
. 2024 Mar;
13(4):745-760.
PMID: 38491269
Introduction: A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions...
5.
Rozenbaum M, Huang L, Perdrizet J, Cane A, Arguedas A, Hayford K, et al.
Vaccine
. 2024 Jan;
42(3):573-582.
PMID: 38191278
Background: As of June 2023, two pneumococcal conjugate vaccines, 20- (PCV20) and 15- (PCV15) valent formulations, are recommended for US infants under a 3 + 1 schedule. This study evaluated...
6.
Rozenbaum M, Begier E, Kurosky S, Whelan J, Bem D, Pouwels K, et al.
Infect Dis Ther
. 2023 Jun;
12(6):1487-1504.
PMID: 37310617
Introduction: Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with respiratory or cardiovascular comorbidities. Published estimates of its incidence and prevalence...
7.
Li X, Warren S, Rozenbaum M, Perdrizet J
Infect Dis Ther
. 2023 Mar;
12(3):997-1006.
PMID: 36867396
Introduction: Studies that estimate the economic burden of pediatric pneumococcal disease often only report direct medical costs and omit indirect non-medical costs. Given these indirect costs are not included in...
8.
Rozenbaum M, Judy J, Tran D, Yacisin K, Kurosky S, Begier E
Infect Dis Ther
. 2023 Jan;
12(2):677-685.
PMID: 36707466
Introduction: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI)-related hospitalizations in older adults. Without RSV-specific treatment for adults, testing is uncommon, leading to potential...
9.
Rozenbaum M, Perdrizet J, Li X, Wasserman M, Grant L, Hayford K, et al.
Infect Dis Ther
. 2022 Nov;
12(1):295-298.
PMID: 36376731
No abstract available.
10.
Schottler M, Coerts F, Postma M, Boersma C, Rozenbaum M
Value Health
. 2022 Aug;
26(1):91-98.
PMID: 35933271
Objectives: Cost-effectiveness analyses (CEAs) generally assume constant drug prices throughout the model time horizon, yet it is known that prices are not constant, often with price decreases near loss of...